Abraham Bassan - 19 Jul 2023 Form 4 Insider Report for Graphite Bio, Inc. (LENZ)

Reporting relationship: Director
Issuer ticker: LENZ
Reported as of: 19 Jul 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 21 Jul 2023, 17:02:57 UTC
Prior SEC filing: 22 Jun 2022
Next SEC filing: 09 Nov 2023
Source filing: View source filing
Reporting owner signature: /s/ Zed Zduniak, attorney-in-fact

Key filing fact

Abraham Bassan filed Form 4 for Graphite Bio, Inc. (LENZ) on 21 Jul 2023.

Key facts

This page summarizes Abraham Bassan's Form 4 filing for Graphite Bio, Inc. (LENZ).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 21 Jul 2023, 17:02.

Change

Previous filing in this sequence was filed on 22 Jun 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

GRPH transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +20,000
Change %
Price: $0.000000
Shares after: 20,000
Date: 19 Jul 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 20,000
Exercise price: $2.72
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The shares subject to such option vest in full on the earlier of (i) the one-year anniversary of the grant date or on (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service as a director as of the applicable vesting date.